Abionyx Pharma Stock: price and insider trades · France

ABIONYX’s core business is centered on research, clinical development, and industrial preparation of apoA-I-based bioproducts. Its main focus areas include sepsis, severe inflammatory diseases, rare disorders, and targeted drug delivery through new HDL vectors. The company also emphasizes a meaningful intellectual property portfolio, with patent families spanning the United States, Europe, Japan, China, and other jurisdictions, supporting the long-term defensibility of its technology platform.

From a market standpoint, ABIONYX PHARMA remains a specialty small-cap biotech at an earlier stage of development, with its therapeutic business still largely pre-commercial. In 2025, consolidated revenue came solely from IRIS Pharma, while the biotechnology activities had not yet generated revenue. Nevertheless, the group has reported a number of recent scientific, regulatory, and financing milestones, including a successful pre-IND meeting with the FDA for CER-001 in sepsis, a positive EMA opinion in LCAT deficiency, Bpifrance support for ophthalmology development, and financing measures extending cash visibility. Taken together, these milestones underline a company in transition, combining science, IP, partnerships, and clinical execution to build long-term value in major unmet-need areas.